Learn about the latest advances in diabetes and other endocrine disorders from the experts of the Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease at Mount Sinai. Our physician-scientists are on the leading edge of diabetes discoveries that have immediate impact on our patients. Andrew Stewart, MD, focuses his research on innovative therapies to regenerate insulin-producing pancreatic beta cells. Carol Levy, MD, directed the first clinical trials for the artificial pancreas. Division Chief Andrea Dunaif, MD, is a leading researcher in genes for polycystic ovary syndrome, a major cause of diabetes in women. We also have multidisciplinary centers of excellence in adrenal, pituitary, and thyroid disorders, as well as in weight management.
The Division of Endocrinology, Diabetes and Bone Disease at The Mount Sinai Hospital is nationally ranked by U.S. News & World Report® for 2024-25. The Division of Endocrinology, Diabetes and Bone Disease at Mount Sinai Morningside and Mount Sinai West is also nationally ranked by U.S. News & World Report® for 2024-25.
Learn about the latest advances in diabetes and other endocrine disorders from the experts of the Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease at Mount Sinai. Our physician-scientists are on the leading edge of diabetes discoveries that have immediate impact on our patients. Andrew Stewart, MD, focuses his research on innovative therapies to regenerate insulin-producing pancreatic beta cells. Carol Levy, MD, directed the first clinical trials for the artificial pancreas. Division Chief Andrea Dunaif, MD, is a leading researcher in genes for polycystic ovary syndrome, a major cause of diabetes in women. We also have multidisciplinary centers of excellence in adrenal, pituitary, and thyroid disorders, as well as in weight management.
The Division of Endocrinology, Diabetes and Bone Disease at The Mount Sinai Hospital is nationally ranked by U.S. News & World Report® for 2024-25. The Division of Endocrinology, Diabetes and Bone Disease at Mount Sinai Morningside and Mount Sinai West is also nationally ranked by U.S. News & World Report® for 2024-25.
Carol J. Levy, MD, and her team are working to expand the use of automated insulin delivery technology—studying its use in insulin-requiring people with type 2 diabetes and during pregnancies complicated by type 1 diabetes.
A team led by Andrea Dunaif, MD, has identified regions of DNA associated with testosterone production in women with polycystic ovary syndrome, bringing the field a step closer to determining the molecular causes of the condition.
A team from the Icahn School of Medicine at Mount Sinai has developed the most comprehensive epidemiological dataset for youth diabetes and prediabetes research, derived from extensive National Health and Nutrition Examination Survey (NHANES) ...
The Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease at the Icahn School of Medicine at Mount Sinai is dedicated to advancing the understanding and treatment of diabetes, obesity, conditions affecting ...
The outstanding faculty in the Division of Endocrinology, Diabetes and Bone Disease continue to make innovative advances in translational research and clinical care. Core to those missions is training the next generation of leaders in our field.
The merger of Mount Sinai’s Endocrinology fellowships into a systemwide, five-hospital program has proved successful in its first two years, with the 14 fellows gaining a wide variety of experience in research and clinical care.
The Diabetes, Obesity and Metabolism Institute made further outstanding progress in 2023 in the study of diabetes, obesity, and metabolic syndromes. The Institute continued its pioneering research in beta cell regeneration and a rising ...
The increasing use of biologic agents for chronic treatment of Crohn’s disease and ulcerative colitis has meant that corticosteroids are typically reserved for use during flares. The intermittent use of these efficacious therapies has ...
A team led by Prashant Rajbhandari, PhD, discovered a family of molecules in the breast called “mammokines” that contribute not only to normal mammary biology, but to overall fat cell physiology and energy balance control.
Patients with multiple myeloma who also have diabetes have reduced overall survival when compared to those without diabetes. However, in a subgroup analysis, this difference in survival due to diabetes was seen in white patients but not in Black patients.
Testosterone treatment for gender-affirming hormone therapy in transmasculine individuals often conjures up safety concerns among prescribing physicians, and patients and their families. However, the largest study of its type to date found ...
Mount Sinai researchers have made breakthrough discoveries about the thyroid-stimulating hormone receptor that suggest new approaches to the treatment of autoimmune thyroid disease.
People who develop diabetes following pregnancy were significantly less likely to be able to bring it under control if they had experienced gestational diabetes mellitus during their pregnancy, especially if they were Black or Hispanic.
A first-of-its-kind study unveils how diabetes drives multiple myeloma growth and differences in survival outcomes for Black versus white patients with both conditions
The Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease at the Icahn School of Medicine at Mount Sinai is dedicated to advancing the understanding and treatment of diabetes, obesity, conditions affecting ...
Mount Sinai was honored by the Juvenile Diabetes Research Foundation at their annual Promise Ball for its type 1 diabetes research and patient care, with particular recognition of Carol J. Levy, MD, and Andrew F. Stewart, MD.
In 2022, investigators advanced the understanding of a broad spectrum of topics relevant to diabetes, metabolism, and obesity, including the central nervous system control of metabolism and therapies to regenerate pancreatic beta cells.
Mount Sinai’s Center for Post-COVID Care is part of a novel, multisite study that is investigating whether abnormal pituitary hormone levels are implicated in post-COVID fatigue, a prevalent and debilitating condition.
Alice C. Levine, MD, convened an interdisciplinary group of experts in adrenal disorders and neuroendocrine tumors to develop a clinical pathway for the management of Cushing syndrome due to ectopic adrenocorticotropin production.
Mount Sinai researchers demonstrated that small molecule DYRK1A inhibitors induce human beta cells to replicate by converting the repressive DREAM complex to its pro-proliferative MMB conformation—a crucial advance in the knowledge of this process.
Endocrinologists and other physicians gained important guidance, as the World Professional Association for Transgender Health released the first update of its standards of care in 10 years.
Emily Gallagher, MD, PhD, received a Method to Extend Research in Time (MERIT) Award from the National Cancer Institute to study the role of high triglyceride levels in driving triple negative breast cancer growth and metastasis.
Use of an automated insulin delivery system improved glucose control among people with type 2 diabetes, representing a potential option for those who are struggling to keep their glucose levels in range.
In an unusual and complex case, a multidisciplinary team developed a treatment for a patient with end-stage liver disease and insulin antibody-mediated insulin resistance.
In a study with the potential to change current practice, a Mount Sinai research team found the risk of blood clots to be minimal, and that patients can safely remain on critical estrogen therapy during their surgery.
A new ambulatory practice, Medicine Multispecialty at Mount Sinai Morningside, was launched in February 2021, dedicated to providing integrated, team-based care that meets the complex needs of patients, especially those with chronic disease.
Two Mount Sinai endocrine surgeons were among the first in the United States to use a novel minimally invasive scar-free thyroidectomy approach, with continuing successful outcomes in more than 100 patients thus far.
Mount Sinai is one of three U.S. sites participating in a clinical trial of an experimental “artificial pancreas” system customized for the stringent glucose targets recommended for optimal maternal and fetal outcomes of pregnancies complicated by diabetes.
